Opinion

Medical marijuana and biosimilars are two topics where 'the will of the people' push decisions

A family-owned pharmaceutical manufacturer plots a 21st-century growth plan

Will formularies become a consumer's concern for healthcare provision?

Internal compliance reviews are not enough; life sciences companies need to assess their third-party business partners

Defining 'market access'

Some state-level changes give an indication of what to prepare for

An 'expectations convergence' is building in how drug efficacy aligns with patient outcomes

The Drug Supply Chain Security Act creates uncertainty about which trading partners have responsibility for product verification

Modern training technologies make the prospect of days-long training courses an obsolete practice

Doing business in China is undergoing important changes

Ultimately, supply chain integrity should include both temperature control and security against theft or diversion

Well designed quality systems follow the product life cycle and foster a culture of quality

Why accreditation?

New reasons why the announced death of this profession will always be premature

What you need to know about the current specialty pharmacy landscape

Things to know about the increasingly popular--and competitive--orphan drug space

PwC's annual forecast of the year's most important healthcare trends

The Health & Personal Care Logistics Conference brings industry leaders together

The Drug Quality and Security Act will change industry for the better

Retailers, distributors and manufacturers are being affected by federal rules on durable medical equipment (DME)

Industry response may be to keep more innovations as trade secrets

The perfect pharmaceutical product would be a pill or injection that, once taken, has a near-immediate beneficial effect.

What are the risks of future 'pay for delay' settlements between branded and generic manufacturers?